Crescita Net Income Per Share from 2010 to 2026

CTX Stock  CAD 0.49  0.02  4.26%   
Crescita Therapeutics Net Loss yearly trend continues to be very stable with very little volatility. Net Loss is likely to grow to -0.13 this year. During the period from 2010 to 2026, Crescita Therapeutics Net Loss quarterly data regression pattern had range of 1.5772 and standard deviation of  0.69. View All Fundamentals
 
Net Loss  
First Reported
2010-12-31
Previous Quarter
(0.13)
Current Value
(0.13)
Quarterly Volatility
0.69307761
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Crescita Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Crescita Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.2 M, Interest Expense of 55.6 K or Selling General Administrative of 10.5 M, as well as many indicators such as Price To Sales Ratio of 0.62, Dividend Yield of 0.0 or PTB Ratio of 0.67. Crescita financial statements analysis is a perfect complement when working with Crescita Therapeutics Valuation or Volatility modules.
  
This module can also supplement various Crescita Therapeutics Technical models . Check out the analysis of Crescita Therapeutics Correlation against competitors.
Evaluating Crescita Therapeutics's Net Income Per Share across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Crescita Therapeutics's fundamental strength.

Latest Crescita Therapeutics' Net Income Per Share Growth Pattern

Below is the plot of the Net Income Per Share of Crescita Therapeutics over the last few years. It is Crescita Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Crescita Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Net Income Per Share10 Years Trend
Slightly volatile
   Net Income Per Share   
       Timeline  

Crescita Net Income Per Share Regression Statistics

Arithmetic Mean(0.65)
Coefficient Of Variation(106.79)
Mean Deviation0.65
Median(0.14)
Standard Deviation0.69
Sample Variance0.48
Range1.5772
R-Value0.86
Mean Square Error0.14
R-Squared0.73
Significance0.000011
Slope0.12
Total Sum of Squares7.69

Crescita Net Income Per Share History

2025 -0.13
2024 -0.14
2023 -0.098
2022 0.0417
2021 -0.0532
2020 0.001791
2019 0.0886

About Crescita Therapeutics Financial Statements

Crescita Therapeutics investors utilize fundamental indicators, such as Net Income Per Share, to predict how Crescita Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Net Loss(0.14)(0.13)

Other Information on Investing in Crescita Stock

Crescita Therapeutics financial ratios help investors to determine whether Crescita Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Crescita with respect to the benefits of owning Crescita Therapeutics security.